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Abstract: Chagas’ disease is an endemic disease in Latin America caused by a unicellular parasite 
(Trypanosoma cruzi) that affects almost 18 million people. This condition involves the heart, 
causing heart failure, arrhythmias, heart block, thromboembolism, stroke, and sudden death. In 
this article, we review the current and emerging treatment of Chagas’ cardiomyopathy focusing 
mostly on management of heart failure and arrhythmias. Heart failure therapeutical options 
including drugs, stem cells and heart transplantation are revised. Antiarrhythmic drugs, catheter 
ablation, and intracardiac devices are discussed as well. Finally, the evidence for a potential role 
of specific antiparasitic treatment for the prevention of cardiovascular disease is reviewed.
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Chagas’ disease is an endemic disease in Latin America caused by a unicellular   parasite, 
Trypanosoma cruzi. Almost 18 million people are infected1 and almost 25% of them will 
develop chronic myocardial disease in the following years or decades. The   intermediate 
phase of the disease, also known as “undetermined phase” (currently a term under 
review, given the fact that several physiopathological mechanisms occur during this 
phase) may last for two to three decades, and the only “  detectable”   manifestation of 
the disease is the immunological reaction and some degree of   autonomic dysfunction. 
Approximately 30% of the infected patients will develop end organ disease (cardiac, 
gastrointestinal, and neurological).2
Although a marked decrease in the incidence has been observed in the last decade 
it is still a major health problem in many countries of Latin America. In 2005, the 
genome sequence of Trypanosoma cruzi was finally discovered, initiating a new era of 
Chagas’ disease treatment based on targeting specific protein kinases and phosphatases.3 
Chronically infected individuals may develop, after the asymptomatic period, chronic 
myocarditis (Figure 1, Panels A and B) and less frequently megacolon, megaesophagus, 
or neurological afflictions.2,4
The main causes of death associated with chronic Chagas’ cardiomyopathy (CChC) 
are progressive congestive heart failure and sudden cardiac death.5,6 Although malignant 
ventricular arrhythmias are thought to be the main cause of sudden death, bradyarrhyth-
mias, and thrombo-embolic events account for some of the sudden death as well.7,8
Chagas’ disease has become a worldwide problem, given the new patterns of 
  immigration. Physicians around the world should become aware of its existence and how 
to recognize and treat it.9 This review is intended to revise the current   therapeutical options 
for the treatment of heart failure and ventricular arrhythmias associated with CChC.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Methods
We reviewed the literature on the current epidemiologic data, 
pathophysiology, and classic and emerging therapeutic options 
for Chagas’ disease. Articles were selected from a computerized 
literature search in the Medline and Scielo databases using the 
keywords: “Chagas”, “Chagas’ disease”, “Chagas’ cardiomyo-
pathy”, “Chagasic disease”, “heart failure”, “antiarrhythmic 
drugs”, “radiofrequency ablation”, “pacemakers”, “implant-
able cardioverter defibrillators”, “stem cells”, and “heart 
transplantation”; and all the possible combinations of the 
above. Two independent investigators (CM, AB) reviewed the 
abstracts and selected the ones considered of interest for the 
review. Discrepancies were resolved by consensus. Personal 
communications with experts were included as well as free 
access database data gained on the Internet. The initial search 
showed 10,393 articles. The combination of keywords narrowed 
this number down to 1,234. We selected 127 abstracts of which 
76 were included in this review. The rest of the references were 
abstracts from proceeding books, book chapters, Internet data-
bases, and personal communications.
Current options for the treatment  
of chronic chagasic cardiomyopathy
Congestive heart failure treatment
In CChC, the hemodynamic and neurohormonal responses 
do not differ from those in other cardiomyopathies; 
treatment of congestive heart failure does not differ 
either. Usual therapeutic strategies such as diuretics, beta 
blockers, angiotensin-converting enzyme inhibitors, and 
spironolactone are likely as important in Chagas’ disease 
as in other heart failure syndromes.10–13 Botoni et al found 
improvements in systolic and diastolic function as well as 
with the neurohormonal parameters using enalapril and 
spironolactone.13 This was consistent with results gained 
by Roberti et al.10 No impact on mortality was reported for 
patients with Chagas’ disease.
Beta blockers have been avoided in patients with CChC 
disease because of bradyarrhyhmias and atrioventricular (AV) 
conduction defects. Botoni et al13 have shown in a double blind, 
placebo-controlled, and randomized trial including 42 patients 
with CChC that optimization of treatment with enalapril and 
spironolactone and subsequent addition of carvedilol were 
safe, hemodynamically well tolerated, and associated with 
an improvement in cardiac function and clinical status. In a 
recently published study, Issa et al14 examined the patients 
included in the REMADHE trial (prospective, randomized, 
single-center open parallel trial; designed to compare a dis-
ease management program versus control in patients with 
chronic heart failure). Patients were grouped according to 
the etiology of the cardiomyopathy (Chagas’ disease versus 
non-Chagas’ disease) and presence of beta blocker therapy. 
A total of 456 patients were included in the study. CChC 
was the etiology in 68 patients (14.9%). In chagasic patients 
beta blocker were used less frequently (35.8% versus 68%; 
P , 0.001). In patients treated with beta blockers the survival 
of patients with Chagas’ disease was similar to that of other 
Figure 1 Panel A) 12-lead eCG depicting the typical conduction disorders associated with Chagas’ disease: Right bundle branch block, left anterior fascicular block,   
1° AV block. Panel B) Chest X-ray (antero-posterior view): increased cardiothoracic index, vascular cephalization. Panel C) iCD stored electrogram depicts VT successfully 
terminated by antitachycardia pacing (grey arrow). Panel D) iCD stored electrogram depicts VT successfully terminated by a shock (black arrow).Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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etiologies. Beta blockers (HR 0.37, 95% CI: 0.14 to 0.97; 
P , 0.044) were associated with better survival.
Antiarrhythmic treatment in Chagas’ disease
Arrhythmias in Chagas’ disease
A wide spectrum of atrial and ventricular arrhythmias and 
conduction disturbances are frequently observed in patients 
with CChC.2,15,16 Sinus node and AV node dysfunction 
(binodal disease) are quite frequent. The most frequent 
manifestation is, by far, persistent sinus bradycardia (with 
or without AV dissociation). Sino-atrial block and sinus 
arrest are also observed as a manifestation of sick sinus 
syndrome. The association of sinus node dysfunction with 
malignant ventricular arrhythmia is very common. The 
use of antiarrhythmic drugs may aggravate the sinus node 
dysfunction unless a permanent pacemaker is implanted.
Ventricular premature contractions (VPCs) and intraven-
tricular conduction disturbances are frequent and maybe pre-
dictors of early myocardial involvement (Figure 1, Panel A). 
VPCs can be demonstrated in about 10% of infected subjects 
without any other evidence of structural heart disease.17 
However, the association of intraventricular conduction 
disturbances and abnormal ventriculogram without cardiac 
failure increases the risk of presenting VPCs in about 56% of 
cases. If cardiac failure is present, the prevalence of VPCs is 
about 85% and is common to detect more complex ventricular 
arrhythmias such as couplets, non-sustained, and sustained 
ventricular tachycardia.17
Electrocardiographic monitoring shows multiform VPCs, 
ventricular parasystole, ventricular escapes, couplets or runs of 
ventricular tachycardia (VT), and R on T phenomenon. VPCs 
with multiple morphologies are the most consistent finding. 
This has been attributed to the widespread foci of myocardial 
damage and correlates with the high prevalence of late poten-
tials when using signal-averaged electrocardiography.18
Our group reported the initiation mode of spontaneous 
malignant ventricular tachyarrhythmias in 179 episodes 
occurring in 15 patients with CChC who had an implantable 
cardioverter defibrillator (ICD), through the analysis of stored 
intracardiac electrograms. A high prevalence of short-long-
short sequences just before the initiation of the malignant 
ventricular tachyarrhythmias was observed. This motivated 
us to speculate in the development of specific software of the 
ICD in order to reduce these short-long-short sequences.19
Sudden cardiac death, usually due to ventricular fibrilla-
tion, is the most common cause of death, and its incidence is 
51%–65% depending on the series.20–23 Malignant ventricular 
arrhythmias are the main cause of sudden cardiac death, 
followed by bradyarrhythmias (high-degree AV block) and 
cerebral emboli.7,8,24
The presence of nonsustained VT detected during 
ambulatory Holter25 monitoring and particularly during stress 
testing26 is a strong predictor of sudden cardiac death. Left 
ventricular (LV) dysfunction is also a predictor of poor outcome, 
particularly if associated with ventricular arrhythmias.8
Antiarrhythmic drugs in Chagas’ disease: past and present
Ventricular tachyarrhythmias in the setting of Chagas’ 
disease are the most serious complications and very difficult 
to treat. Ventricular arrhythmias are usually unsustained but 
they can degenerate into malignant forms. Drug therapy is 
frequently ineffective to control the arrhythmia.
Almost all of the widely used antiarrhythmic agents have 
been used in patients with Chagas’ disease.17 Unfortunately, 
these trials usually have been uncontrolled, noninvasively 
guided, or empiric, and with short-term follow-up. No drug 
has been shown to prolong survival in a randomized trial. In 
comparative studies using ambulatory electrocardiography, 
Haedo et al27 and Rosenbaum et al28 showed that amiodarone 
is the most effective of the antiarrhythmic agents and is 
relatively well tolerated. Patients with malignant arrhythmias 
treated with amiodarone and followed for 26 months with 
ambulatory ECG, had only few minor arrhythmic events.29 
In another study30 there was a low risk of arrhythmia recur-
rence or death when the LV ejection fraction (EF) was above 
30%, but there was a 100% recurrence rate and 80% mor-
tality if patients had New York Heart Association (NYHA) 
class III–IV with an EF less than 30%.
Invasively guided antiarrhythmic drug therapy seems to 
offer a good method for risk stratification and drug selection 
in patients with symptomatic sustained or non sustained VT. 
Sustained VT is inducible in more than 80% of patients with 
clinical sustained VT and in 50% of those presenting with 
syncope.31
In another study, Sarabanda et al analyzed ventricular 
arrhythmia inducibility in patients with sustained and non-
sustained VT in patients with Chagas’ disease. They found 
induction of sustained VT by programmed ventricular 
stimulation in 89% of patients with clinical presentation of 
sustained VT and in 7% in patients with non sustained VT.32
Leite et al33 used electrophysiologic testing to evalu-
ate 115 patients. After loading amiodarone in 115 patients; 
electrophysiologic testing identified three groups: nonsustained 
VT was inducible (Group 1, n = 23); only tolerated sustained 
monomorphic VT was inducible (Group 2, n = 45); and non-
tolerated sustained monomorphic VT was inducible (Group 3, Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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n = 47). Over a mean follow up of 52 ± 32 months, total 
mortality was significantly higher among group 3 than in 
groups 1 or 2; 29 (61.7%), 6 (26.1%), and 10 (22.2%); (HR 
10.4; P , 0.0001). No significant differences in total mortal-
ity were observed between groups 1 and 2. Electrophysiologic 
testing can be used to stratify the risk of symptomatic patients 
with VT associated with CChC; who are being treated with 
class III antiarrhythmic drugs.
Implantable cardioverter-defibrillators in Chagas’ disease
ICDs are the first line therapeutical option for primary and 
secondary prevention of sudden death34–38 in the setting of 
coronary artery disease or nonischemic disease with depressed 
LV function. Because of its frequent association with sudden 
cardiac death, Chagas’ disease has become an emerging 
indication for ICDs (Figure 1, Panels C and D). However the 
efficacy and safety in treating patients with Chagas’ disease 
have been assessed in only few studies.39–41
Last year, we reported on the clinical impact of ICD ther-
apy in patients with Chagas’ disease treated for prevention of 
sudden death.42 The Medtronic ICD Registry is an international 
registry containing data on patients with CChC implanted with 
an ICD in Latin America. This registry includes data from 
patients living in Puerto Rico, the Caribbean, Mexico, and 
South America. All patients were implanted with a Medtronic 
ICD. We analyzed data from 89 patients with CChC implanted 
with ICD, 91% of them due to secondary prevention. After a 
mean follow-up of 12 months, the total mortality was 6.7%. 
A total of 737 episodes of ventricular tachyarrhythmias in 38 
patients were detected. ICD shocks were delivered in 35 epi-
sodes (4.8%), antitachycardia pacing in 554 (75.1%), and both 
in 107 (13.1%). Forty one episodes (5.6%) had spontaneous 
reversion. Appropriate ICD intervention rates were similar 
in patients presenting with sudden death (50%), VT with 
hemodynamic deterioration (50%) or without hemodynamic 
deterioration (47%), or unexplained syncope (50%).
This international registry confirmed that ICD therapy 
provided protection by effectively terminating life-
  threatening arrhythmias in patients with Chagas’ disease. 
This was especially so when patients were implanted due to 
secondary prevention purposes.
Cardinalli-Neto et al41 recently reported the largest single 
center experience on ICD implantation in Chagas’ disease 
patients. They analyzed 90 patients receiving an ICD for second-
ary prevention. During a mean follow-up of 756 ± 581 days, 
31 of 90 patients (34%) died. The total mortality rates were 
18%, 27%, 40%, 50%, and 73%, after 1, 2, 3, 4, and 5 years, 
respectively. The number of shocks per patient by day 30 was 
found to be the only independent predictor of all-cause mortality 
(HR 1.86, 95% CI: 1.21 to 2.86; P  = 0.005). In our experience, 
of over 148 chagasic patients with ICD we found that age older 
than 65 years old (HR 2.85, CI: 1.77–3.92; P  = 0.041) and EF 
less than 30% (HR 2.68, CI: 1.57–3.79; P  = 0.039) were inde-
pendent predictors of all cause mortality at one year.43
Chagas’ disease patients receiving an ICD respond similarly 
to ischemic patients,39 although they tend to experience more 
shocks.44 Our group reported the time to occurrence of 
first appropriate ICD shock in 55 patients, 20 with CChC 
and 35 with ischemic disease. During the first 6 months of 
follow up, 35 of the 55 patients (66.6%) received at least one 
appropriate spontaneous ICD shock; 17/20 chagasic patients 
(85%) versus 18/35 ischemic patients (51%) received one 
ICD shock (RR: 1,65; P , 0.02).44 The cumulative incidence 
of shocks at 1, 2, 3, and 6 months post-implant in chagasic 
patients and ischemic patients was 55%, 10%, 10%, and 10% 
versus 14%, 11.5%, 8.5%, and 17%, respectively.
Permanent pacemakers in Chagas’ disease
Recommendations for permanent cardiac pacing in CChC 
are similar to other diseases and were previously published. 
Symptoms and probably the life expectancy of patients with 
Chagas’ disease are improved by permanent ventricular 
pacing.45 Recently, Vanegas reported that the main reasons 
for implanting a pacemaker in patients with Chagas’ disease 
were: sinus node dysfunction (52%); second and third degree 
AV block (26%), and atrial fibrillation with AV block or 
trifascicular block (21%).46
Tentori et al47 reported over 177 patients that the main 
causes for pacemaker implantation were: sick sinus syndrome 
(SSS) 32.2%, complete AV block 41.2%, 2:1 AV block 
9.6%, trifascicular block 4.7%, AV block plus SSS 2.8%, 
and atrial fibrillation with low ventricular response 7.2%. 
Indication for pacing due to SSS was more prevalent in 
females (43.8%) versus males (15.9%); P , 0.001. Atrial 
fibrillation developed in 34 patients (21 with third degree AV 
block versus 13 with SSS, P = 0.45) at a mean follow-up of 
86 months post pacemaker implant.
Garcia Rincon et al48 reported that chagasic patients 
implanted with permanent pacemakers were younger 
(55 versus 68 years old; P , 0.001), with lower LVEF 
(55 versus 60%; P , 0.04) and with more frequent ventricular 
arrhythmias in Holter monitoring than implanted patients 
with no Chagas’ disease.48
Despite sick sinus syndrome being the most frequent 
reason for implantation, single-chamber ventricular pacing is 
frequently used to treat these patients.46,49 Some economical 
limitations may account for this medical decision but lack of 
official data makes this comment purely speculative.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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The dyssynchrony induced by right apical ventricular 
pacing may contribute to the development of dilated car-
diomyopathy in this predisposed group of patients. Dual 
chamber pacemakers with specific algorithms may help to 
minimize unnecessary ventricular pacing. Alternative sites 
of pacing have not been systematically studied yet.
Transcatheter ablation in patients with Chagas’ disease
VT is common among patients with Chagas’ disease but the 
ultimate mechanisms are not completely understood. Slow 
conduction scarred areas are related to VT arrhythmogenesis 
in CChC; the LV inferolateral scar areas are the main source 
of sustained VT reentrant circuits.32
Chagasic patients tend to be younger and have higher 
LVEF than their counterparts with ischemic disease. It is 
assumed, therefore, that their prognosis is closely related to 
VT treatment rather than the progression of the myocardial 
damage caused by the disease itself.50 The VT recurrence rate, 
despite best possible treatment with amiodarone, remains 
high and usually poses a clinical challenge.
Radiofrequency (RF) ablation, both delivered in the 
endocardium and the epicardium have been demonstrated 
to reduce the recurrence of VT, as a single treatment or 
in combination with an ICD. Other sources than RF, like 
infrared laser, have been experimentally tested with promis-
sory results.50
The initial reports on successful VT RF ablation in cha-
gasic patients were reported more than 10 years ago.51,52 Since 
then, the evolution of the mapping techniques as well as the 
approach from the epicardium has expanded this technique 
to a larger number of patients.
In a recent study both the endocardium and epicardium of 
patients with CChC and VT referred for electrophysiologic 
study and radiofrequency ablation have been characterized.53 
Seventeen patients were prospectively evaluated using a 
simultaneous epicardial and endocardial electroanatomical 
substrate mapping. With a mean of 201 ± 94 epicardial and 
169 ± 77 endocardial points, the epicardial voltage areas with 
less or equal to 0.5 mV were 56.8 ± 40.6 cm2 as compared to 
22.5 ± 15.8 cm2 in the endocardium (P = 0.004). Analyzing the 
epicardial surface, there was a strong correlation between the 
bipolar voltage electrograms and the electrogram duration at 
the epicardium during sinus rhythm (r = 0.897; P , 0.0001). 
Acute success was obtained in 83.3% of patients.53
In a reported case, ablation of the mitral isthmus has also 
been referred to as a necessary approach to control of VT 
with two different morphologies that was using the isthmus 
as part of the circuit.54 Unfortunately, this patient presented a 
massive cerebral infarction that led to death. The prevention 
of this complication is of particular importance in chagasic 
patients given the higher prevalence of apical aneurysms and 
intracardiac thrombus.
A fairly constant finding in the reported cases is the 
multiple VT morphologies and cycle lengths, leading to long 
procedures, extensive ablations, and weaker endpoints. We 
speculate that as it happens in patients with ischemic VT, 
RF ablation in addition to an ICD may reduce the incidence 
of therapies delivered by the device.55
Resynchronization therapy  
in Chagas’ disease
Cardiac resynchronization therapy (CRT) has become an 
established treatment for patients with moderate to severe 
heart failure, wide QRS complex, optimized heart failure treat-
ment, and evidence of ventricular dyssynchrony. Randomized 
controlled clinical trials have shown that CRT improves 
NYHA functional class, exercise capacity, quality of life, and 
hemodynamics and reduces morbidity and mortality.56–59
Current heart failure treatment guidelines published jointly 
by the American College of Cardiology and the American Heart 
Association reflect these findings.60 They recommend CRT for 
patients with NYHA functional class III or ambulatory class 
IV heart failure who are refractory to optimal medical therapy 
and have sinus rhythm, a QRS duration .120   milliseconds, and 
a LVEF , 35%. Although these guidelines included the pres-
ence of sinus rhythm, data from European studies suggested 
that patients with atrial fibrillation may also benefit from CRT 
if the heart rate is properly controlled.61
Careful patient selection is vital to successful CRT results. 
The speculation of which patients may benefit from CRT is 
mostly based on the results of clinical trials. No patients with 
CChC were included in these large trials.
Actually, only few papers with small numbers of patients 
have been published to date. Alves Fagundes et al62 recently 
reported their experience on CRT implantation in Chagas’ dis-
ease patients. They analyzed 19 patients within a mean follow 
up of 24.7 ± 20 months. The LVEF improved from 28% ± 5% 
to 32.2% ± 11% and the NYHA functional class decreased 
from 3.5 ± 0.5 to 2.5 ± 0.8. No differences were found when 
compared with ischemic or idiopathic dilated cardiomyopathy 
patients.
Despite the lack of larger series, CRT is also a promising 
therapy for patients with CChC and refractory heart failure.
Cell therapy in patients  
with Chagas’ disease
Heart transplantation is the only available option for patients 
with heart failure that failed optimum pharmacological and Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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electrical treatment. There are several limitations to performing 
heart transplantation in patients with Chagas’ disease, not only 
because its high costs and the scarcity of donated organs, but 
also because the need of immunosup  pressive agents after 
transplantation that may reactivate latent infections.
The discovery of stem cells capable of differentiating 
into specialized cell types has opened new avenues for the 
treatment of heart failure due to CChC. This therapy is able 
to ameliorate heart disease caused by chronic infection with 
Trypanosoma cruzi, repairing the heart tissue damaged by 
the pathological process using the patient’s own cells.
Vilas-Boas et al63 published the first report on this topic in 
2006. The efficacy of the therapy was evaluated in 28 patients in 
whom 50 mL of bone marrow aspirate was collected from each 
patient by multiple punctures of the two iliac crests. A significant 
improvement in several parameters during a 60 day follow-up 
also sug  gested a potential benefit of the therapy. These included 
improvements in NYHA functional class (3.1 ± 0.3 to 1.8 ± 
0.5; P , 0.0001), the   Minnesota quality of life questionnaire 
(50.9 ± 11.7 to 21.8 ± 13.4; P , 0.0001), the distance walked 
in six minutes (355 ± 136 m to 443 ± 110 m; P = 0.003), and 
the LVEF (20.1 ± 6.8% to 23.0 ± 9.0%, P = 0.02).63
Trainini et al64 showed their experience in five patients 
with cell therapy in chagasic patients with heart failure 
NYHA III/IV . At 17.2 ± 8.8 months, 4 patients were alive and 
with NYHA I (P , 0.005). One patient died suddenly after 
17 months of follow up. An increase of the ejection fraction 
was observed (27.6% ± 5.9% to 36.6% ± 2.3%; P , 0.05). 
During the follow up no adverse events were observed in 
none of the patients referred for cellular implantation.
A phase III clinical trial sponsored by the Brazil  ian Ministry 
of Health is being concluded. This protocol is a double-blind 
placebo controlled randomized clinical trial aimed at evaluat-
ing the efficacy of bone marrow derived stem cell implants in 
300 chronic chagasic Brazilian patients with dilated cardiomyo-
pathy and heart failure NYHA III or IV . The primary endpoint of 
this study is to evaluate the effect of the autologous bone marrow 
stem cell implant in the increment of the LVEF in comparison 
with a control group, under optimized therapy for dilated car-
diomyopathy. Secondary endpoints will evaluate the changes 
in NYHA functional class, mortality rate, physical capacity (by 
ergoespirometry), quality of life (Minnesota questionnaire), and 
pulmonary congestion.65
Antiparasitic treatment in the 
“undetermined” phase: possible 
cardiovascular implications
Benznidazole, a nitroimidazole derivative, has been recom-
mended for the treatment of acute and congenital Trypanosoma 
cruzi infection.66 Recent data indicates that parasite persistence 
plays a pivotal role in the pathogenesis of chronic CChC.67 
More recently, it has been demonstrated that the reduction 
of the parasite in the body may prevent the development 
of cardiomyopathy.68 However, the efficacy of trypanocidal 
therapy in preventing clinical complications in patients with 
preexisting cardiac disease is unknown. BENEFIT is a multi-
center, randomized, double-blind, placebo-controlled clinical 
trial intended to recruit 3,000 patients with CChC in Latin 
  America.69 BENEFIT will clarify the role of trypanocidal 
therapy in preventing cardiac disease progression and death. 
Patients will be randomized to receive benznidazole (5 mg/
kg per day) or matched placebo, for 60 days. The primary out-
come will be the composite of death; resuscitated cardiac 
arrest; sustained VT; insertion of pacemaker or ICD; cardiac 
transplantation; and development of new heart failure, stroke, 
or systemic or pulmonary thromboembolic events. The aver-
age follow-up time will be 5 years, and the trial has a 90% 
power to detect a 25% relative risk reduction. Recruitment 
started in November 2004; so far, 1,916 patients have been 
enrolled [Argentina (423), Brazil (987), Bolivia (191), and 
Colombia (315)].70 El Salvador and Spain (Chagas’ disease, 
as a consequence of changes in immigration patterns during 
the last decade, has been expanded outside South America);9 
have been invited to participate and the trial is being revised by 
the correspondent health bodies. About 90% of the randomized 
patients presented heart failure NYHA class I–II and 63% had 
a positive basal (before treatment) PCR. A total enrollment of 
2,700 patients is expected by the end of 2010.
Heart transplantation
Indications for heart transplantation in patients with chronic 
heart failure secondary to CChC is debatable and somewhat 
difficult to implement, in comparison to non-Chagas’ disease 
patients.71,72
There have been many concerns with regard to the usefulness 
of heart transplantation in Chagas’ disease patients due to the 
lack of proper indications for the procedure, the pathogenesis of 
the disease, the adequate immunosuppressive protocol, Trypano-
soma cruzi infection reactivation, and long-term results.
Survival rates from studies following patients with severe 
chronic heart failure due to several etiologies indicated that 
patients with CChC and severe heart failure have a 1 year 
survival rate of 40% to 70%, depending on the series.73–76 
Another study showed 1-year survival probability is 20% in 
patients with NYHA IV and a LVEF , 30%.77
Recently, Dib et al78 found that patients with Chagas’ dis-
ease heart failure listed for heart transplantation on inotropic 
support have an annual probability of mortality of 100%.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
599
Chagas’ Cardiomyopathy
Bocchi and Fiorelli79 reported a multicentric study. 
They included 792 patients that underwent orthotopic 
heart transplantation in 16 centers in Brazil. The etiology 
was idiopathic dilated cardiomyopathy in 407 patients, 
ischemic cardiomyopathy in 196 patients, CChC in 117 
patients, and others in 72 patients. This study showed that 
the probability of survival after heart transplantation in 
patients with CChC was at 1 year, 2 years, 6 years, and 10 
years follow-up 71%, 62%, 55%, and 46%, respectively. 
Survival of chagasic recipients was significantly better in 
comparison with idiopathic and ischemic cardiomyopathy 
(P , 0.027). The small sample size did not allow to take 
definitive conclusions and these results should be confirmed 
with larger studies. Trypanosoma cruzi reactivations may 
occur after transplantation, leading to higher morbidity and 
graft dysfunction. Trypanosoma cruzi reactivations occurred 
between 27% and 39% of Chagas’ disease patients.80 Bocchi 
et al79 surprisingly showed a low incidence of reactivation 
of Trypanosoma cruzi infection manifested as myocarditis 
and meningoencephalitis as cause of death (0.3%). Other 
series with less number of patients confirmed the results 
obtained in this study.81–84
Heart transplantation remains controversial as a useful 
therapeutical option in patients with Chagas’ disease.
Future directions
Chagas’ disease poses a unique challenge in current 
  medicine. The epidemiology, pathophysiology, vectors, and 
urgent medical interventions have been clearly identified by 
decades. However, only few advances in the total eradication 
of this disease have been made in the last years.
Why? It is a very complex, intricate problem and mul-
tifactorial in nature. Political decisions and public health 
policies are needed. International collaboration including 
economical support from developed countries may be needed 
to correct one of the major problems associated with this 
disease: poverty.
In the meantime, investigators from all around the world 
are contributing to the better understanding of the disease. 
Studies in the field of genetic interventions are ongoing. The 
BENEFIT study will shed light on the usefulness of antipara-
sitic treatment for the prevention of chronic cardiac forms.
Major advances in the comprehension and treatment of 
associated cardiac arrhythmias are being carried out; it is 
difficult to predict where we are going to be 10 years from 
now. We advocate for a major investment in improving hous-
ing conditions and developing public health strategies that 
will have a necessary impact in the current inadmissible high 
prevalence of Chagas’ disease.
Conclusions
Chagas’ disease is a serious public health problem in Central 
and South America. Major efforts are being implemented 
to control this endemic disease. Public health policies and 
house improving are necessary components of the changes 
being put into practice.
Cardiac involvement is the most frequent and serious 
clinical manifestation of the disease. As a result of changes 
in the immigration pattern, CChC is now encountered outside 
of the endemic countries, especially in the United States and 
Spain. Rapid recognition of this condition as well as knowing 
the available therapeutical options is of utmost importance 
for the cardiologist.
The manifestations of CChC are the result of progressive 
damage to the myocardium, extracellular matrix, cardiac 
autonomic innervation, and possibly the coronary microvessels. 
CChC often mimics ischemic heart disease and the commonly 
used noninvasive tests cannot reliably distinguish them. Prog-
nosis depends largely on the extent of myocardial damage and is 
particularly poor when left ventricular dysfunction, aneurysms, 
or both are present. Ventricular arrhythmias in these patients 
are exceptionally malignant. RF ablation and ICDs became 
therapeutical alternatives for the treatment of these patients.
Implementing public health policies and continuing 
understanding the complex pathophysiology of the disease 
hold the promise that this fascinating and deadly disease can 
be controlled.
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